Evogene Ltd. Increases ATM Offering and Discloses Activist Shareholder Campaign to Replace Board

On July 17, 2026, Evogene Ltd. announced an increase in its 'at-the-market' (ATM) offering program. The company amended its existing Sales Agreement with A.G.P./Alliance Global Partners to increase the maximum aggregate offering price of its ordinary shares from $2,926,500 to $3,288,113, adding approximately $361,613 in available capacity. In addition to the financing update, Evogene disclosed significant governance challenges. The company updated its risk factors to address ongoing shareholder activism. Specifically, a group of shareholders filed a Schedule 13D demanding an extraordinary general meeting to remove and replace almost the entire Board of Directors, excluding the CEO. Evogene warned that responding to this proxy contest could divert management resources from its core biotechnology R&D, increase share price volatility, and potentially lead to a fundamental shift in corporate strategy if the activists are successful. The company is dual-listed on Nasdaq and the Tel Aviv Stock Exchange, which may amplify market volatility resulting from these disputes.